10 completed, 3 unknown, 1 enrolling by invitation, 1 not yet recruiting. 16 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 16 | Completed 10, Unknown 3, Enrolling by invitation 1, Not yet recruiting 1, Recruiting 1 |
| Phase 2 | 5 | Completed 3, Enrolling by invitation 1, Unknown 1 |
Follow Central Nervous System Bacterial Infections: new trials by email Literature Review of Central Nervous System Bacterial Infections trials Research Report on Central Nervous System Bacterial Infections
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase Ia Clinical Trial of Group ACYW135X Meningococcal Conjugate Vaccine high-dose Group ACYW135X Meningococcal Conjugate Vaccine, medium-dose Group ACYW135X Meningococcal Conjugate Vaccine, low-dose Group ACYW135X Meningococcal Conjugate Vaccine - Meningococcal Meningitis | Phase 1 | Not yet recruiting | Sinovac Life Sciences Co., Ltd. | 150 | 2026-01-21 | 2026-01-28 |
| Clinical Trial of the Adsorbed Acellular Pertussis (Tricomponent) DTaP-Haemophilus Influenzae Type b (Conjugate)-ACYW135 Group Meningococcal (Conjugate) Combined Vaccine Adsorbed Acellular Pertussis (3-Component) Diphtheria-Tetanus-Pertussis-Haemophilus influenzae type b (Conjugate)-Meningococcal Group ACYW135 (Conjugate) Combined Vaccine (DTcP-Hib-MCV4), DTcP-Hib-MCV4, Adsorbed Acellular Pertussis (3-Component) Diphtheria-Tetanus-Pertussis (DTcP) - Diphtheria, Tetanus and Acellular Pertussis, Epidemic Meningitis | Phase 1 | Recruiting | CanSino Biologics Inc. | 260 | 2025-12-19 | 2025-12-31 |
| Phase II Clinical Study of Contezolid for the Treatment of Tuberculous Meningitis Contezolid, Linezolid (LZD) - Tuberculosis, Meningitis | Phase 1 / Phase 2 | Enrolling by invitation | Beijing Chest Hospital | 24 | 2024-02-01 | 2025-02-06 |
| Safety Evaluation of Meningococcal Group ACYW135 Conjugate Vaccine in 2-month to 55 Years Old Population. Meningococcal Group ACYW135 Conjugate Vaccine - Meningococcal Infections | Phase 1 | Completed | Walvax Biotechnology Co., Ltd. | 100 | 2018-07-17 | 2020-01-22 |
| Optimizing Treatment to Improve TBM Outcomes in Children High-dose: RIF, INH, PZA, EMB, High dose: RIF, INH, PZA, LEVO, Standard of care: RIF, INH, PZA, EMB - Tuberculosis, Meningeal | Phase 1 / Phase 2 | Completed | Johns Hopkins University | 38 | 2017-02-22 | 2021-10-28 |
| Study Assessing the Safety, Immunogenicity and Dose Response of VLA15, A New Vaccine Candidate Against Lyme Borreliosis VLA15 with Alum, VLA15 without Alum - Lyme Borreliosis, Nervous System | Phase 1 | Completed | Pfizer | 179 | 2017-01-31 | 2023-04-05 |
| Immunogenicity and Safety of Meningococcal Groups A and C and Haemophilus b Conjugate Vaccine in Infants 2 to 5 Months of Age Meningococcal Groups A and C and Haemophilus b Conjugate Vaccine (adjuvant-free), Meningococcal Groups A and C and Haemophilus b Conjugate Vaccine(adjuvant) - Meningitis, Meningococcal Meningitis | Phase 1 / Phase 2 | Unknown | Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd | 360 | 2016-08-01 | 2016-09-29 |
| Safety Study of Meningococcal ACYW135 Polysaccharide Conjugate Vaccine in Healthy Volunteers Aged Above 3 Months Meningococcal ACYW135 Polysaccharide Conjugate Vaccine - Meningitis, Meningococcal | Phase 1 | Unknown | Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd | 200 | 2016-06-01 | 2016-08-26 |
| A Single-center, Open Trials to Evaluate the Safety of Freeze-dried Group ACYW135 Meningococcal Conjugate Vaccine freeze-dried group ACYW135 MCV - Meningococcal Meningitis | Phase 1 | Unknown | Lanzhou Institute of Biological Products Co., Ltd | 200 | 2015-06-01 | 2015-06-25 |
| Safety and Immunogenicity Study in Young Adults the Meningococcal Serogroup C Vaccine Produced by Bio-Manguinhos 'MenCC-Bio', MENJUGATE - Meningitis, Meningococcal, Serogroup C | Phase 1 | Completed | The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) | 60 | 2014-05-01 | 2015-09-16 |
| Safety Study of Group A, C, Y & W-135 Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine for Meningitis meningococcal meningitis conjugate vaccine, quadrivalent - Meningococcal Meningitis, Meningococcal Infections | Phase 1 | Completed | JN-International Medical Corporation | 60 | 2011-11-01 | 2013-01-14 |
| Study Evaluating Safety And Tolerability Of Meningococcal B Rlp2086 Vaccine In Healthy Adults rLP2086 vaccine or control - Meningitis, Meningococcal | Phase 1 | Completed | Pfizer | 48 | 2009-04-01 | 2015-08-06 |
| Safety And Blood Collection Study Of Meningococcal B Rlp2086 Vaccine In Adults meningococcal B rLP2086 vaccine candidate, Blood draw - Meningitis, Meningococcal | Phase 1 / Phase 2 | Completed | Wyeth is now a wholly owned subsidiary of Pfizer | 60 | 2008-10-01 | 2011-08-23 |
| Exploratory Trial to Evaluate the Safety and Immunogenicity of Menactra® and Menomune® Vaccines in Subjects ≥ 56 Years Menomune®: A, C, Y, W-135 Meningococcal Polysaccharide, Menactra®: Polysaccharide Diphtheria Toxoid Conjugate - Meningococcal Infections, Meningococcal Meningitis | Phase 1 / Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 216 | 2007-10-01 | 2013-09-20 |
| Study Evaluating the Safety, Immunogenicity and Tolerability of Meningococcal Group B Vaccine in Healthy Adults MnB rLP2086 - Meningitis, Meningococcal | Phase 1 | Completed | Wyeth is now a wholly owned subsidiary of Pfizer | 108 | 2006-03-01 | 2007-12-05 |
| Safety and Immunogenicity Study of Group B Meningococcal Vaccine to Prevent Meningitis. 25ug Group B Meningococcal 44/76 MOS NOMV 5D Vaccine, 50ug Group B Meningococcal 44/76 MOS NOMV 5D Vaccine - Meningitis, Meningococcal, Serogroup B | Phase 1 | Completed | U.S. Army Medical Research and Development Command | 34 | 2005-12-05 | 2018-10-29 |
Meningitis, Meningococcal (13) · Meningococcal Infections (4) · Meningitis (3) · Tuberculosis, Meningeal (2) · Central Nervous System Infections (1) · Diphtheria (1) · Haemophilus Infections (1) · Lyme Disease (1) · Lyme Neuroborreliosis (1) · Tetanus (1) · Tuberculosis (1)
Bacterial Infections (16) · Bacterial Infections and Mycoses (16) · Central Nervous System Diseases (16) · Infections (16) · Nervous System Diseases (16) · Central Nervous System Infections (15) · Meningitis, Bacterial (15) · Neuroinflammatory Diseases (15) · Gram-Negative Bacterial Infections (14) · Neisseriaceae Infections (13) · Meningitis (12) · Meningococcal Infections (9) · Actinomycetales Infections (3) · Gram-Positive Bacterial Infections (3)
Blood Specimen Collection (1) · CRM197 (non-toxic variant of diphtheria toxin) (1) · Control Groups (1) · HibTITER protein, Haemophilus influenzae (1) · Isoniazid (1) · Levofloxacin (1) · Linezolid (1) · Meningococcal Vaccines (1) · NSC 366140 (1) · Rifampin (1) · Saline Solution (1) · Sodium Chloride (1) · Vaccines, Combined (1) · aluminum sulfate (1) · contezolid (1)
Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd (2) · Pfizer (2) · Wyeth is now a wholly owned subsidiary of Pfizer (2) · Beijing Chest Hospital (1) · CanSino Biologics Inc. (1) · JN-International Medical Corporation (1) · Johns Hopkins University (1) · Lanzhou Institute of Biological Products Co., Ltd (1) · Sanofi Pasteur, a Sanofi Company (1) · Sinovac Life Sciences Co., Ltd. (1) · The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) (1) · U.S. Army Medical Research and Development Command (1) · Walvax Biotechnology Co., Ltd. (1)
China (6) · United States (5) · Australia (2) · Belgium (1) · Brazil (1) · India (1) · Malawi (1)
Barnett Gibbs, MD (1) · Kelly Dooley, MD,PhD (1) · Paul B Keiser (1) · Sudesh Nagavalli, MD (1) · Yanxia Wang (1)
PMID 35164991, PMID 22832260, PMID 23352429, PMID 35291004, PMID 37419129
R01HD074944 (1)